LABORATORY NEWS
-
PhAST Corp. Receives FDA Clearance For Rapid Antimicrobial Susceptibility Testing Directly From Positive Blood Cultures
PhAST Corp., an in vitro diagnostics company building a single-cell computer vision platform for rapid phenotypic testing across clinical microbiology, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the PhAST instrument and the PhAST Blood Culture Gram-negative Panel (PhAST BC GN Panel, K253316), granted June 2026.
- Werfen Announces US FDA 510(k) Clearance And CE Mark For Aptiva® Antiphospholipid Syndrome IgA Reagent
- Bionano Laboratories Announces Expansion Of Diagnostic Testing Based On Optical Genome Mapping For Hematologic Malignancies
- Mayo Clinic Laboratories Invests In Pathology Asia Holdings And LifeStrands Genomics To Advance Diagnostics And Precision Medicine
- BioEdge Research Labs Announces Quality-Control Measures For Research Materials
ARCHIVED NEWSLETTER
- 09.22.26 -- Sakura Finetek Europe Launches Sakura Pathology Network
- 08.25.26 -- GHK-Cu Peptide Launched By Kylo Peptides For Laboratory Research Applications
- 07.21.26 -- Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches
- 07.07.26 -- A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
- 05.26.26 -- Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics